For many years, experts have debated the value of prostate cancer screening. A recent analysis of data from two major trials involving prostate-specific antigen testing revealed that early tumor detection lowers a man’s risk of prostate cancer death by 25% to 32%. The American Cancer Society’s Dr. Otis Brawley reports that the review provides some much-needed “clarity in an area where there was at one time a great deal of confusion.”
Annals of Internal Medicine, September 2017